Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia
暂无分享,去创建一个
T. Naoe | M. Taniwaki | M. Tanimoto | S. Iida | A. Utsunomiya | T. Nagai | K. Tobinai | K. Ishizawa | K. Ando | R. Ohno | I. Jinnai | H. Sakamaki | Y. Miyazaki | S. Miyawaki | Y. Morishima | T. Seriu | M. Okada | S. Okamoto | S. Fujisawa | N. Uoshima | K. Ohnishi | T. Motoji | N. Usui
[1] J. Bajpai. Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial , 2008 .
[2] Andreas Hochhaus,et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Baccarani,et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) , 2008 .
[4] M. Kurosawa,et al. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group , 2007, European journal of haematology.
[5] J. Radich,et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. , 2007, Blood.
[6] R. Larson,et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.
[7] M. Baccarani,et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.
[8] M. Baccarani,et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.
[9] 松尾 江美. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia : a study in Nagasaki Prefecture, Japan , 2007 .
[10] Francisco Cervantes,et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.
[11] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[12] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[13] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[14] C. Sawyers,et al. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[16] Munir Pirmohamed,et al. Active transport of imatinib into and out of cells: implications for drug resistance. , 2004, Blood.
[17] M. Ogura,et al. Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study , 2004, International journal of hematology.
[18] Yun Dai,et al. A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2* , 2004, Journal of Biological Chemistry.
[19] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[20] A. Hochhaus,et al. Clinical resistance to imatinib: mechanisms and implications. , 2004, Hematology/oncology clinics of North America.
[21] O. Witte,et al. The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.
[22] G. Ehninger,et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate , 2004, Leukemia.
[23] N. Donato,et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.
[24] A. Gotoh,et al. Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients? , 2003, International journal of hematology.
[25] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[26] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[27] J. Issa,et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[29] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[30] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[31] C Chastang,et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.
[32] Sante Tura,et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.